Lineage Cell Therapeutics, Inc. Lease Obligation Incurred
Lineage Cell Therapeutics, Inc. (LCTX) reported Lease Obligation Incurred of $151.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-14.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2019-03-14
- Lineage Cell Therapeutics, Inc. lease obligation incurred for the quarter ending 2014-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. lease obligation incurred for the quarter ending 2014-09-30 was $0.00.
- Lineage Cell Therapeutics, Inc. lease obligation incurred for the quarter ending 2013-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. lease obligation incurred for the quarter ending 2013-09-30 was $0.00.
- Lineage Cell Therapeutics, Inc. lease obligation incurred for fiscal 2017 was $151.00K, a 75.88% decline from fiscal 2016.
- Lineage Cell Therapeutics, Inc. lease obligation incurred for fiscal 2016 was $626.00K, a 1741.18% increase from fiscal 2015.
- Lineage Cell Therapeutics, Inc. lease obligation incurred for fiscal 2015 was $34.00K, a 70.43% decline from fiscal 2014.
- Lineage Cell Therapeutics, Inc. lease obligation incurred for fiscal 2014 was $115.00K.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 6 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|---|
| 2017-12-31 | $151.00K 10-K · filed 2019-03-14 | |||
| 2016-12-31 | $626.00K 10-K · filed 2018-03-15 | |||
| 2015-12-31 | $34.00K 10-K · filed 2018-03-15 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $0.00 derived: sum of 2 quarters · filed 2017-03-16 | $115.00K 10-K · filed 2017-03-16 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $115.00K 10-Q · filed 2014-11-07 | ||
| 2014-06-30 | $115.00K 10-Q · filed 2014-08-11 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $0.00 derived: sum of 2 quarters · filed 2016-03-15 | $0.00 10-K · filed 2016-03-15 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $0.00 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-11 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |